Now showing items 1-20 of 191

    • A decade of clinical development of PARP inhibitors in perspective. 

      Mateo, J; Lord, CJ; Serra, V; Tutt, A; Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; Oaknin, A; Kaye, SB; de Bono, JS (2019-09)
      Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce ...
    • A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

      Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; Kwak, EL; Macarulla Mercadé, T; Geuna, E; Jose de Miguel-Luken, M; Patel, C; Kuida, K; Sankoh, S; Westin, EH; Zohren, F; Shou, Y; Tabernero, J (2017-09)
      <b>Purpose:</b> To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid ...
    • A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. 

      Mateo, J; Ganji, G; Lemech, C; Burris, HA; Han, S-W; Swales, K; Decordova, S; DeYoung, MP; Smith, DA; Kalyana-Sundaram, S; Wu, J; Motwani, M; Kumar, R; Tolson, JM; Rha, SY; Chung, HC; Eder, JP; Sharma, S; Bang, Y-J; Infante, JR; Yan, L; de Bono, JS; Arkenau, H-T (2017-10)
      <b>Background:</b> The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target ...
    • A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. 

      Kolinsky, MP; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; Mateo, J; Michalarea, V; Riisnaes, R; Crespo, M; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Flohr, P; Tunariu, N; Banerji, U; Ruddle, R; Sharp, A; Welti, J; Lambros, M; Carreira, S; Raynaud, FI; Swales, KE; Plymate, S; Luo, J; Tovey, H; Porta, N; Slade, R; Leonard, L; Hall, E; de Bono, JS (2020-05)
      Background Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence ...
    • A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. 

      Spicer, J; Irshad, S; Ang, JE; Enting, D; Kristeleit, R; Uttenreuther-Fischer, M; Pemberton, K; Pelling, K; Schnell, D; de Bono, J (2017-01)
      Purpose The combination of afatinib, an irreversible ErbB family blocker, with paclitaxel and bevacizumab was assessed in patients with advanced solid tumors.Methods This phase I study used a 3 + 3 design to determine the ...
    • A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. 

      O'Brien, MER; Sarker, D; Bhosle, J; Thillai, K; Yap, TA; Uttenreuther-Fischer, M; Pemberton, K; Jin, X; Wiebe, S; de Bono, J; Spicer, J (2018-11)
      Purpose Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.Methods As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 ...
    • A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. 

      Tiu, C; Shinde, R; Yap, C; Rao Baikady, B; Banerji, U; Minchom, AR; de Bono, JS; Lopez, JS (2020-07)
    • A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. 

      Ferrarini, A; Forcato, C; Buson, G; Tononi, P; Del Monaco, V; Terracciano, M; Bolognesi, C; Fontana, F; Medoro, G; Neves, R; Möhlendick, B; Rihawi, K; Ardizzoni, A; Sumanasuriya, S; Flohr, P; Lambros, M; de Bono, J; Stoecklein, NH; Manaresi, N (2018-01)
      Chromosomal instability and associated chromosomal aberrations are hallmarks of cancer and play a critical role in disease progression and development of resistance to drugs. Single-cell genome analysis has gained interest ...
    • A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. 

      Ingles Garces, AH; Ang, JE; Ameratunga, M; Chénard-Poirier, M; Dolling, D; Diamantis, N; Seeramreddi, S; Sundar, R; de Bono, J; Lopez, J; Banerji, U (2018-11)
      Background The incidence and clinical significance of electrolyte abnormalities (EAs) in phase I clinical trials are unknown. The objective of this study is to evaluate the incidence and severity of EAs, graded according ...
    • A study of motivations and expectations of patients seen in phase 1 oncology clinics. 

      Dolly, SO; Kalaitzaki, E; Puglisi, M; Stimpson, S; Hanwell, J; Fandos, SS; Stapleton, S; Ansari, T; Peckitt, C; Kaye, S; Lopez, J; Yap, TA; van der Graaf, W; de Bono, J; Banerji, U (2016-11)
      Background To better inform clinical practice, this study was aimed at capturing patients' motivations for enrolling in phase 1 trials and at quantifying their expectations of the benefits, risks, and commitment associated ...
    • A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. 

      Minchom, A; Thavasu, P; Ahmad, Z; Stewart, A; Georgiou, A; O'Brien, MER; Popat, S; Bhosle, J; Yap, TA; de Bono, J; Banerji, U (2017-01)
      We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected ...
    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      Background Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ...
    • Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. 

      Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; de Bono, JS; Attard, G; Chowdhury, S; Cross, WR; Dearnaley, DP; Brawley, CD; Gilson, C; Ingleby, F; Gillessen, S; Aebersold, DM; Jones, RJ; Matheson, D; Millman, R; Mason, MD; Ritchie, AWS; Russell, M; Douis, H; Parmar, MKB; Sydes, MR; Clarke, NW; STAMPEDE Investigators
      Background Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ...
    • Acquiring evidence for precision prostate cancer care. 

      Mateo, J; Carreira, S; de Bono, JS (2017-05)
    • Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. 

      Li, S; Fong, K-W; Gritsina, G; Zhang, A; Zhao, JC; Kim, J; Sharp, A; Yuan, W; Aversa, C; Yang, XJ; Nelson, PS; Feng, FY; Chinnaiyan, AM; de Bono, JS; Morrissey, C; Rettig, MB; Yu, J (2019-05)
      Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. Transcriptome analysis of multiple prostate cancer models ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
    • Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. 

      Neeb, A; Herranz, N; Arce-Gallego, S; Miranda, S; Buroni, L; Yuan, W; Athie, A; Casals, T; Carmichael, J; Rodrigues, DN; Gurel, B; Rescigno, P; Rekowski, J; Welti, J; Riisnaes, R; Gil, V; Ning, J; Wagner, V; Casanova-Salas, I; Cordoba, S; Castro, N; Fenor de la Maza, MD; Seed, G; Chandran, K; Ferreira, A; Figueiredo, I; Bertan, C; Bianchini, D; Aversa, C; Paschalis, A; Gonzalez, M; Morales-Barrera, R; Suarez, C; Carles, J; Swain, A; Sharp, A; Gil, J; Serra, V; Lord, C; Carreira, S; Mateo, J; de Bono, JS (2020-11-08)
      Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond.Objective To characterise ATM-deficient ...
    • Alternative splicing in prostate cancer. 

      Paschalis, A; Sharp, A; Welti, JC; Neeb, A; Raj, GV; Luo, J; Plymate, SR; de Bono, JS (2018-11)
      Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain ...
    • An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. 

      Thiery-Vuillemin, A; Fizazi, K; Sartor, O; Oudard, S; Bury, D; Thangavelu, K; Ozatilgan, A; Poole, EM; Eisenberger, M; de Bono, J
      Background Men with metastatic castration-resistant prostate cancer (mCRPC) are living longer, therefore optimizing health-related quality of life (HRQL), as well as survival outcomes, is important for optimal patient care. ...